Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Identification and assessment of markers of biotin status in healthy adults.

Eng WK, Giraud D, Schlegel VL, Wang D, Lee BH, Zempleni J.

Br J Nutr. 2013 Jul 28;110(2):321-9. doi: 10.1017/S0007114512005065. Epub 2013 Jan 10.

2.

Use of COMPARE analysis to discover new natural product drugs: isolation of camptothecin and 9-methoxycamptothecin from a new source.

Zhou BN, Hoch JM, Johnson RK, Mattern MR, Eng WK, Ma J, Hecht SM, Newman DJ, Kingston DG.

J Nat Prod. 2000 Sep;63(9):1273-6.

PMID:
11000035
3.

Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway.

Chaturvedi P, Eng WK, Zhu Y, Mattern MR, Mishra R, Hurle MR, Zhang X, Annan RS, Lu Q, Faucette LF, Scott GF, Li X, Carr SA, Johnson RK, Winkler JD, Zhou BB.

Oncogene. 1999 Jul 15;18(28):4047-54.

4.

The yeast FKS1 gene encodes a novel membrane protein, mutations in which confer FK506 and cyclosporin A hypersensitivity and calcineurin-dependent growth.

Eng WK, Faucette L, McLaughlin MM, Cafferkey R, Koltin Y, Morris RA, Young PR, Johnson RK, Livi GP.

Gene. 1994 Dec 30;151(1-2):61-71.

PMID:
7530227
5.

Catalytic and ligand binding properties of the FK506 binding protein FKBP12: effects of the single amino acid substitution of Tyr82 to Leu.

Bossard MJ, Bergsma DJ, Brandt M, Livi GP, Eng WK, Johnson RK, Levy MA.

Biochem J. 1994 Jan 15;297 ( Pt 2):365-72.

6.

Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity.

Cafferkey R, Young PR, McLaughlin MM, Bergsma DJ, Koltin Y, Sathe GM, Faucette L, Eng WK, Johnson RK, Livi GP.

Mol Cell Biol. 1993 Oct;13(10):6012-23.

7.

The tyrosine89 residue of yeast FKBP12 is required for rapamycin binding.

Koser PL, Eng WK, Bossard MJ, McLaughlin MM, Cafferkey R, Sathe GM, Faucette L, Levy MA, Johnson RK, Bergsma DJ, Livi GP.

Gene. 1993 Jul 30;129(2):159-65.

PMID:
8325502
8.

Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content.

Woessner RD, Eng WK, Hofmann GA, Rieman DJ, McCabe FL, Hertzberg RP, Mattern MR, Tan KB, Johnson RK.

Oncol Res. 1992;4(11-12):481-8.

PMID:
1338578
9.

The CYP2 gene of Saccharomyces cerevisiae encodes a cyclosporin A-sensitive peptidyl-prolyl cis-trans isomerase with an N-terminal signal sequence.

Koser PL, Bergsma DJ, Cafferkey R, Eng WK, McLaughlin MM, Ferrara A, Silverman C, Kasyan K, Bossard MJ, Johnson RK, Porterd TG, Levy MA, Livi GP.

Gene. 1991 Dec 1;108(1):73-80.

PMID:
1761234
10.

Expression of human recombinant cAMP phosphodiesterase isozyme IV reverses growth arrest phenotypes in phosphodiesterase-deficient yeast.

McHale MM, Cieslinski LB, Eng WK, Johnson RK, Torphy TJ, Livi GP.

Mol Pharmacol. 1991 Feb;39(2):109-13.

PMID:
1847489
11.

Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.

Eng WK, McCabe FL, Tan KB, Mattern MR, Hofmann GA, Woessner RD, Hertzberg RP, Johnson RK.

Mol Pharmacol. 1990 Oct;38(4):471-80.

PMID:
2172765
12.
13.

Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.

Tan KB, Mattern MR, Eng WK, McCabe FL, Johnson RK.

J Natl Cancer Inst. 1989 Nov 15;81(22):1732-5.

PMID:
2553992
14.

Mapping of the active site tyrosine of eukaryotic DNA topoisomerase I.

Eng WK, Pandit SD, Sternglanz R.

J Biol Chem. 1989 Aug 15;264(23):13373-6.

15.

Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin.

Eng WK, Faucette L, Johnson RK, Sternglanz R.

Mol Pharmacol. 1988 Dec;34(6):755-60.

PMID:
2849043
16.

Supplemental Content

Support Center